Company ProfilePremium

Guangdong Hybribio Biotech Co., Ltd.

Company Profile Analysis

Ticker: 300639.SZ广东凯普生物科技股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Guangdong Hybribio Biotech Co., Ltd. - Company showcase

Year Founded & Workforce

2003

10 Employees

Guangdong Hybribio Biotech Co., Ltd. logo

Guangdong Hybribio Biotech Co., Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Guangdong Hybribio Biotech Co., Ltd. Overview

Hybribio is a Chaozhou-based, founder-controlled Chinese molecular-diagnostics company that built its franchise on HPV genotyping using a proprietary flow-through hybridisation platform originally licensed from the University of Hong Kong. Its HPV21 kit was the first HPV test in China to receive a new-drug certificate and its core patent won the 18th China Patent Gold Award. The company later integrated downstream into independent clinical laboratories (27 licensed labs across China and Hong Kong) and, since 2024, a private hospital in Chaozhou. COVID-19 testing transformed its scale—revenue peaked at RMB 5.6 bn in FY2022—but the post-pandemic unwind, national volume-based procurement (VBP) of HPV-DNA tests, a VAT increase on reagents, and large impairments on pandemic-era government receivables produced losses in FY2024–FY2025. In H1 2026 it returned to a small profit. The investment case now hinges on receivable recovery, new-assay mix (methylation, pharmacogenomics, mRNA triage), lab restructuring, and a debt-light balance sheet supporting buybacks.


Company's own description (FY2025 Annual Report, paraphrased)

The company describes itself as a leading domestic integrated provider of molecular diagnostic products and services, organised around three mutually reinforcing business pillars: (1) molecular diagnostic products, (2) medical laboratory testing services, and (3) medical "big health" services. Products cover tumour early screening, infectious disease and hereditary disease testing—specifically oncology tests, communicable disease tests, maternal and child health management and birth-defect prevention—used in hospital clinical diagnosis, birth-defect prevention programmes and public-health screening. The laboratory network is positioned on molecular diagnostics as the core technology with high-end specialty testing (metagenomics, tumour early screening, tandem mass spectrometry, high-density gene chips) as the growth direction. The health-services pillar centres on Chaozhou Kaipu Kanghe Hospital and a physical examination centre, tied together through the "Kaipu Kanghe Medical Testing 5.0" (凯普康和医检5.0) system, which uses an internet hospital as the carrier and the national lab network as the fulcrum to serve both B2B and B2C customers.

Business model and revenue model

Revenue streamModelCustomersEvidence (source, period)
Self-produced reagents & instruments (自产产品)Product sales; direct sales to key hospitals plus buy-out distribution through annually contracted distributorsPublic hospitals, maternal & child health (MCH) institutions, CDCs, screening programmes, distributorsH1 2026 self-produced product revenue RMB 173 M, gross margin 77.13% (2026 Interim, via CFI.cn)
Purchased (third-party) products (外购产品)ResaleSame as aboveH1 2026 RMB 11.07 M (2026 Interim)
Medical laboratory testing servicesFee-for-test outsourcing contracts; co-built hospital labsHospitals (incl. primary care), government health commissions (2020–22 pandemic testing)H1 2026 RMB 95.46 M, gross margin 13.58% (2026 Interim)
Medical services (hospital)Fee-for-service clinical care, health check-ups, online consultationsPatients, corporate check-up clients, insurers (planned)FY2025 hospital revenue RMB 27.49 M; H1 2026 RMB 20.90 M, gross margin −38.40%
OtherLeasing, misc.—H1 2026 RMB 2.0 M

There is no subscription or licensing revenue of significance disclosed. The company's IT platforms (two-cancer screening management, birth-defect screening management, pathology management, LIS, regional lab platform, medical expert database) are positioned as solution add-ons, but separate revenue is not disclosed.

Value-chain position

Hybribio sits across three links of the IVD value chain: (i) upstream assay development and reagent/instrument manufacturing (Chaozhou and Guangzhou production bases, ISO 13485/MDSAP-certified); (ii) midstream testing services via its own ICL network; and (iii) downstream care delivery via a hospital and internet hospital. It is also attempting to move further upstream through minority investments in sequencing-instrument developers (Chengdu Jinshi Zhixu, Shenzhen Salus) and into therapeutics (two anti-HPV topical drug candidates).

End-markets

Women's health (cervical cancer screening, reproductive tract infections), birth-defect prevention (thalassaemia, hereditary deafness, G6PD deficiency, chromosomal aneuploidy, SMA), infectious disease (HBV, respiratory pathogens, CMV, GBS), pharmacogenomics/precision medication (clopidogrel, warfarin, statins, folate, psychiatric drugs, APOE for Alzheimer's risk), and cancer early detection (cervical, bladder, nasopharyngeal methylation). Geographically, the business is overwhelmingly domestic (overseas revenue RMB 13.34 M in H1 2026, ~4.4% of revenue).

Independent characterisation

Hybribio is best understood as a niche HPV/women's-health diagnostics franchise that over-expanded into labour- and capital-intensive lab services during the pandemic and is now in a multi-year right-sizing. The reagent business remains highly profitable at the gross level (74.6% gross margin in H1 2026) despite VBP, whereas lab services barely cover direct costs (13.6% gross margin) and the hospital is loss-making. The single largest driver of reported earnings in 2024–2026 has not been operations but the provisioning cycle on ~RMB 1.08 bn of gross pandemic-era receivables from local governments—an item whose reversal (H1 2026 credit-impairment write-back of RMB 30.4 M) now flatters profit just as its build-up depressed FY2024.

Strategy

Stated strategy themes (FY2025 AR)

"Three business pillars" synergy: molecular diagnostic products, medical lab services and medical health services.

"Kaipu Kanghe Medical Testing 5.0": integrates the three pillars using the hospital as cornerstone, the internet hospital as carrier and 20+ labs as fulcrum; four business lines (tumour early screening; online B2C testing; full-cycle cancer management; diabetes management).

"Nucleic Acid 99" (and "999") strategy: continuous launch of new nucleic-acid assays; >60 projects in development across infectious disease, genetics, metagenomics, methylation and mass spectrometry.

2026 operating theme: "Restructure, upgrade, develop" — strengthen HQ direct management, empower provincial management groups, create a national bidding-management centre ("bid on everything, raise win rate"), rebuild national distributor system, launch national distributor recruitment for new products, push the industry chain down to consumers.

AI & data assetisation: roll out the "Wuxian" medical AI brain (Hybribio/ComeWell WuXian AI Brain); build a master-data platform across R&D, registration, screening, diagnosis, treatment and health management; pursue AI product registrations in tumour screening.

Internationalisation: more country registrations; Hong Kong lab as springboard to South-East Asia.

Initiatives in the last 24 months

InitiativeDetailDateSource
Lab network restructuring31→27 labs; exit low-margin routine tests; focus on specialty testingFY2025FY2025 AR
Kanghe hospital ramp-upFirst full year; RMB 27.49 M revenue; internet hospital licence; 5 new departments and linac in 20262025–26FY2025 AR
Wuxian AI Brain"Ten Shamans" digital-employee team covering service, data entry, interpretation, report review, alerting2,025FY2025 AR
Market Value Management SystemAdopted by board10 Dec 20242026 Interim
Share buybacks2025 programme (treasury stock RMB 110.1 M at Sep 2025); 2026 programme RMB 75–150 M2025–26Q3 2025 report; Caiwen News
Receivable recovery driveExecutive-led task force; litigation; engagement with State Council departments; leverage local-government debt-swap policies2024–26FY2025 AR
Capex pacingSuspension of Medical Science Park hospital and conference-centre constructionFY2025FY2025 AR
ESG/communityUp to RMB 30 M charitable donations (2026); RMB 20 M donated to Guangdong basic research joint fund (138 projects funded cumulatively)2026; cumulativeSZSE Q&A June 2026; FY2025 AR
Cultural platform"Lingdong Humanities Network"; acquisition of the "Changguangli" media operatorFeb 2026FY2025 AR

Medium-term targets / guidance

No quantitative revenue or margin guidance is published. Management's qualitative targets for 2026: improve lab-segment cost control, expand non-VBP HPV products (mRNA, methylation) and the four key product series, increase profitability overall. The company expects lab services and hospital to remain loss-making in the short term (FY2025 AR risk section).

Products & Services

Registration base at end-FY2025: 97 domestic device registrations/filings (34 Class III, 6 Class II, 56 Class I filings, 1 Hong Kong listed Class C), 59 CE certifications of which 26 under EU IVDR (FY2025 AR).

Molecular diagnostics — Cervical cancer / HPV franchise

ProductDescription & capabilityTarget customerStatus / notes
HPV21 genotyping kitFlow-through hybridisation, 21 HPV types; first HPV test in China with a new-drug certificate; core patent won 18th China Patent Gold AwardHospitals, screening programmesMarketed; legacy flagship
HPV37 genotyping kitDetects 37 types — company states most types among marketed HPV tests in ChinaTertiary hospitals, epidemiologyMarketed
HPV12+214 high-risk types; first in China approved for primary cervical screening, co-testing and ASC-US triage claims beyond aided diagnosisNational "two-cancer" screeningMarketed; widely used in public screening
HPV14 genotypingCovers the 14 high-risk types in the WHO cervical precancer screening guidelineScreeningMarketed
High-risk HPV E6/E7 mRNA testTriage of ASC-US-positive cytology patientsHospitalsMarketed; outside national VBP
Cervical cancer methylation testTriage of HPV-positive women; registered deviceHospitalsMarketed; outside VBP
Usage metricsCumulative HPV test usage >83 M; ~8.6 M person-tests in FY2025; 10 consecutive WHO HPV LabNet proficiency rounds; >1,650 papers using the products—FY2025 AR
VBP positionKaipu Chemical first by reported demand in national HPV-DNA VBP (3.37 M person-tests, 24.17%); competitive in 25 alliance provinces—FY2025 AR. Pricing model: VBP tender pricing; ex-factory prices fell sharply (exact prices not disclosed)

Birth-defect prevention

ProductDescriptionStatus
Thalassaemia gene testFlagship hereditary test (α/β-thalassaemia), cumulative ~4.4 M usesMarketed; nanopore-sequencing version in development
Hereditary deafness susceptibility gene testCumulative ~3.4 M uses; company co-drafted NMPA industry standard; >300 deafness-gene demonstration basesMarketed
G6PD gene testGlucose-6-phosphate dehydrogenase deficiency (favism)Marketed
CMV nucleic-acid testHuman cytomegalovirusMarketed
Group B Streptococcus nucleic-acid testPerinatal GBSMarketed
Y-chromosome microdeletion testMale infertilityMarketed
Chromosome (13/18/21/X/Y) multiplex STR kit (fluorescent PCR–capillary electrophoresis)Detects seven aneuploidy types in amniotic fluid plus maternal cell contamination; co-developed with Guangdong Women and Children HospitalRegistered 4 Mar 2026
SMA gene testSpinal muscular atrophy (fluorescent PCR and MALDI-TOF platforms)Clinical trial
HPV/thalassaemia cell-line reference materialsQC materialsDeveloped

Reproductive tract infection (STD) and infectious disease

ProductDescriptionStatus
STD series (single, 2-plex, 3-plex, 10-plex)Gonorrhoea, chlamydia, ureaplasma, M. genitalium, M. hominis, HSV-2 etc.; cumulative >4.85 M usesMarketed
Vaginal microbiome 3-plex nucleic-acid kitVaginal microecologyRegistration stage
Multi-pathogen reproductive-tract kitsExpansion of STD panelDevelopment
HBV gene testHepatitis B; usage +32.35% YoY in FY2025Marketed
HBV high-sensitivity testLow viral-load detectionClinical trial
Respiratory 6-plexInfluenza A/B, RSV, adenovirus, M. pneumoniae and othersRegistered in FY2025
Respiratory single-plex testsSubsets of the aboveDeveloped
SARS-CoV-2 nucleic-acid testCOVID-19Marketed (demand largely gone)
Norovirus nucleic-acid kitGastroenteritisRegistration stage
Chikungunya/dengue nucleic-acid kitArbovirusesClinical trial

Pharmacogenomics / precision medication

ProductGene targetsUse
Human CYP2C19 gene testCYP2C19Clopidogrel response
CYP2C9 & VKORC1 gene testCYP2C9, VKORC1Warfarin dosing
MTHFR gene testMTHFRFolate supplementation
ALDH2 gene testALDH2Nitroglycerin response, alcohol metabolism
APOE & SLCO1B1 polymorphism testAPOE, SLCO1B1Statin myopathy risk; Alzheimer's early risk assessment
Psychiatric drug-concentration testsMass-specTherapeutic drug monitoring
Vitamin and endocrine panelsTandem mass spectrometryLDT/lab use

The nine "push" products (Y-microdeletion, CMV, GBS, G6PD, MTHFR, ALDH2, CYP2C9/VKORC1, CYP2C19, APOE/SLCO1B1) generated close to RMB 25 M in FY2025 (FY2025 AR).

Oncology early detection

ProductStatus
Cervical cancer methylationRegistered
Bladder cancer methylationClinical trial
Nasopharyngeal carcinoma methylation (3 patents/technologies licensed from Sun Yat-sen University Cancer Center)Clinical trial
Endometrial cancer methylationResearch
Pan-cancer early screening service package (risk assessment → pan-cancer → single-cancer)Offered via Kanghe 5.0

Instruments, consumables and IT

Sample processing, nucleic-acid extraction and molecular hybridisation instruments and consumables (exact models not disclosed in reviewed documents). Six IT platforms: two-cancer health management platform with cytopathology AI-assisted diagnosis, birth-defect screening management platform, pathology diagnosis management platform, medical laboratory LIS, Kaipu regional medical testing platform, Kaipu medical expert database. "Wuxian Medical AI Brain" (multimodal LLM + proprietary medical knowledge base + agent "digital employees") deployed for customer service, data entry, result interpretation and report review.

Therapeutics pipeline

CandidateIndicationStage
Chloroquine phosphate gel (improved new drug)HPV-induced skin warts, genital and perianal condylomaPhase II completed; Phase III imminent (FY2025 AR; Sept 2026 IR)
Anti-HPV vaginal gelHigh-risk HPV infectionPhase II

Medical laboratory services

27 licensed labs; >85,000 m² floor space; several hundred high-end instruments (tandem MS, NGS, immunochemistry and molecular automation lines); ~2,000 test items across hereditary metabolic disease, infectious disease, molecular pathology, cytogenetics and genetic counselling, tumour genomics, pharmacogenomics, endocrinology, gynaecology and reproductive-tract metagenomics; CNAS/ISO 15189 quality system. Platforms: LC-MS/MS, nucleic-acid MS, ICP-MS, microbial MALDI; multi-channel qPCR, digital PCR, molecular POCT; pathogen mNGS and tNGS.

Medical "big health" services

Chaozhou Kaipu Kanghe Hospital: ~27 mu site, ~16,000 m² first phase, 200 planned beds (100 open); cores in oncology (led by CMO Prof. Li Xiaochuan, tenured professor of radiation oncology, Medical College of Wisconsin), orthopaedics, and health management; specialties in blood purification and digestive endoscopy; 16 clinical and 4 medical-technology departments, with oncology, psychiatry, general surgery, medical aesthetics and radiotherapy to be added in 2026; linear accelerator planned. Online: Kanghe internet hospital (licensed 2025), "Kaipu Tong" and "Kanghe Mall" WeChat mini-programs with >400 test/risk-assessment items; home nurse visits via partners. Kanghe 5.0 business lines: tumour early screening, online B2C testing, full-cycle cancer management, diabetes (chronic disease) management.

Financial Narrative

Sources: FY2021–FY2022 restated figures from FY2023 AR summary (restatement due to accounting-policy change); FY2023–FY2025 from FY2024 AR and FY2025 AR summary; gross profit and total net profit FY2024–FY2025 from Pharnexcloud filing extracts of the annual reports.

Income statement

Revenue CAGR FY2021–FY2025 (calc.): −29.2% p.a.

Quarterly run-rate

2026 year-to-date: Q1 2026 revenue RMB 125.8 M with net profit of about −RMB 2.8 M (SZSE.io summary of Q1 report); H1 2026 revenue RMB 300.0 M (−4.74% YoY) and attributable net profit RMB 31.26 M (vs −RMB 89.59 M), implying Q2 2026 revenue of ~RMB 174 M and attributable profit of ~RMB 34 M (calc.).

H1 2026 income-statement detail (2026 Interim)

Commentary: the H1 2026 turnaround is of mixed quality. Of a ~RMB 120 M swing in attributable profit, roughly RMB 88 M came from the credit-impairment swing (−57.6 → +30.4), RMB 42 M from halved selling expense, RMB 16 M from higher FX-driven financial income and RMB 6 M from fair-value gains. Gross profit actually fell slightly (RMB 148 M → RMB 142 M).

Balance sheet

Additional verified balance-sheet items:

Net debt is strongly negative (net cash of roughly RMB 0.9–1.0 bn at end-2025 on verified items: RMB 1,038.7 M cash/deposits less ~RMB 97 M borrowings, calc.).

Cash flow

FY2021 OCF is derived from the reported FY2022 OCF of RMB 1,309.2 M and its disclosed 107.37% growth (calc.). FY2025 cash received from sales of goods and services was RMB 1,078.0 M—1.6x revenue—evidencing collection of old receivables.

Ratios

Leverage is immaterial (debt ratio ~12%, borrowings <RMB 100 M), so interest-coverage risk is low; the relevant working-capital metric is receivables, where net receivables (RMB 697 M) exceed a full year of revenue.

Trend commentary

The five-year series is a complete boom-bust cycle. Revenue more than doubled in FY2022 on COVID testing (lab services were 77.6% of H1 2022 revenue), then collapsed 80% in FY2023 as testing ended. FY2024 combined three negatives: (i) the end of residual COVID revenue, (ii) HPV VBP price cuts, and (iii) large credit impairments on government receivables plus reversal of deferred tax assets, producing a RMB 655 M attributable loss. FY2025 revenue fell another 17.9% because of the first full year of HPV VBP and the 3%→13% VAT change on self-produced reagents, but the loss narrowed 80% as credit impairments fell by RMB 573 M. The inflection to profitability in H1 2026 rests on cost cuts and provisioning reversals rather than top-line growth (revenue still −4.7%).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipSegmentNotes (source)

Chaozhou Kaipu Biochemical Co., Ltd. (凯普化学)

100%

MDx products

National "little giant" specialised SME; H1 2026 net profit RMB 47.09 M (+151.98%) (2026 Interim)

Guangzhou Kaipu Medical Laboratory Development Co., Ltd. (凯普医学检验)

81.10%

Lab services

H1 2026 net loss RMB 29.94 M, loss narrowed by RMB 133.42 M YoY (2026 Interim)

Hong Kong Molecular Pathology Laboratory Ltd. (香港检验中心)

Controlled

Lab services

Total assets RMB 770.0 M at 30 Jun 2026 (2026 Interim)

Hybribio (Hong Kong) (凯普生物(香港))

100%

Trading/investment

Total assets RMB 1,441.8 M; H1 2026 net profit RMB 24.40 M, mainly FX gains

Hong Kong Kaipu Biotech Co., Ltd.

100%

Trading

Total assets RMB 10.3 M

Guangzhou Kaipu Medicine Technology Co., Ltd. (凯普医药)

100%

R&D

Joint research centre with Xiamen University

Guangzhou Kaipu Biotechnology Co., Ltd.

100%

R&D / drug project

Anti-HPV drug project co-implementer

Guangzhou Kaipu Pharmaceutical Manufacturing Co., Ltd.

100%

Drug manufacturing

Added as anti-HPV drug implementer Nov 2024

Guangdong Kaipu Medical Technology Industry Co., Ltd.

100%

Medical Science Park

Borrower under syndicated loan; 100% equity pledged (2026 Interim)

Chaozhou Kaipu Kanghe Hospital

Group-operated

Medical services

100 of 200 planned beds open

Revenue by Segment

Segment (CNY Mn)H1 2021H1 2022H1 2026

Molecular diagnostic products revenue

445.0637.3184.0

Medical laboratory services revenue

853.02,205.095.46

Medical services (hospital) revenue

——20.90

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment gross margin (%)

Segment gross margin (%)H1 2022H1 2026

Molecular diagnostic products

74.3774.64

Medical laboratory services

67.0513.58

Medical services (hospital)

—-38.40

Group

—47.34

Segment Overview

SegmentRevenue CNY Mn% of totalGross profit CNY Mn

Molecular diagnostics

184.061.3%137.0

Lab services

95.4631.8%12.97

Medical services

20.907.0%−8.03

Total

300.0100%142.0

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

2,673.05,597.01,104.5815.5669.6

Revenue YoY growth (%)

—109.4-80.3-26.2-17.9

Gross profit (CNY Mn)

———388.8304.5

Gross margin (%)

———47.745.5

Net profit incl. minorities (CNY Mn)

———-950.4-182.3

Net profit attributable to shareholders (CNY Mn)

852.51,726.0140.5-654.9-130.9

Net profit attributable, excl. non-recurring (CNY Mn)

841.11,734.5113.2-659.7-171.0

Net margin, attributable (%) (calc.)

31.930.812.7-80.3-19.6

Basic EPS (MYR Bn)

—2.620.25-1.02-0.21

Diluted EPS (MYR Bn)

—2.620.25-1.02-0.21

Weighted ROE (%)

—42.352.88-14.62-3.34

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

MetricQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025

Revenue (CNY Mn)

183.1225.8201.4205.3134.1180.9170.9183.8

Attributable net profit (CNY Mn)

-14.4-62.6-185.0-393.0-27.3-62.3-38.1-3.3

Operating cash flow (CNY Mn)

-64.130.877.634.446.98.565.8220.4

Income Statement (Half-Yearly)

Line item (CNY Mn)H1 2025H1 2026YoY

Revenue

315.0300.0-4.7%

Cost of revenue

167.0158.0-5.4%

Selling expense

90.749.1-45.9%

Admin expense

101.295.3-5.8%

Financial expense (negative = income)

-21.8-37.7

FX gain on RMB appreciation

R&D investment

41.534.0-18.2%

Credit impairment (positive = reversal)

-57.630.4

reversal of receivable allowances

Asset impairment

-10.9-0.4—

Fair-value gains

4.410.1

revaluation of equity stakes

Income tax

10.015.0+50.5%

Net profit incl. minorities

-137.125.4—

Net profit attributable

-89.631.3—

Operating cash flow

55.470.7+27.6%

Investing cash flow

258.8-129.2

equity investments and capex

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

4,239.56,741.25,725.84,623.04,147.7

Equity attributable to shareholders (CNY Mn)

3,194.64,907.24,861.34,109.43,748.4

Equity / total assets (%) (calc.)

75.472.884.988.990.4

Book value per share (MYR Bn)

—7.949.076.305.87

Financial Analysis

ItemValueDate / source

Cash, time deposits and structured deposits

RMB 1,038.7 M

31 Dec 2025, FY2025 AR

Cash & cash equivalents (cash-flow statement basis)

RMB 708.0 M

31 Dec 2025, CFI.cn

Cash & cash equivalents

RMB 388.9 M

31 Mar 2026 (shift into wealth-management products)

Wealth-management balance

RMB 638.0 M (of which RMB 140 M raised funds)

30 Jun 2026, 2026 Interim

Short-term borrowings

RMB 1.0 M (vs RMB 21.6 M end-2024)

30 Sep 2025, Q3 2025 report

Long-term borrowings

RMB 95.6 M (vs RMB 52.8 M end-2024), mainly special buyback loan

30 Sep 2025

Treasury stock

RMB 110.1 M (vs RMB 65.1 M end-2024)

30 Sep 2025

Accounts receivable — gross

RMB 1,645.3 M

31 Dec 2025

Allowance for doubtful accounts

RMB 948.3 M

31 Dec 2025

Accounts receivable — net

RMB 697.0 M

31 Dec 2025

Of which pandemic-era (2020–22) receivables, gross / net

RMB 1,075.1 M / RMB 231.3 M

31 Dec 2025

Goodwill

~RMB 5.1 M

Q1 2026 (SZSE.io)

Debt-to-assets ratio

11.93%

Q1 2026 (SZSE.io)

Factored receivables (restricted)

RMB 10.1 M

30 Jun 2026

Undistributed profit

RMB 2,332.2 M

FY2025 (cited in SZSE investor Q&A)

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

631.31,309.2319.678.8341.6

OCF / attributable net profit (x) (calc.)

0.740.762.28——

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025

ROE, weighted (%)

42.352.88-14.62-3.34

ROA, attributable NI / avg total assets (%) (calc.)

31.42.3-12.7-3.0

Asset turnover, revenue / avg total assets (x) (calc.)

1.020.180.160.15

Revenue by Region and Revenue by Region (%)

RegionH1 2022H1 2026

Domestic revenue (CNY Mn)

1,962.0287.0

Overseas revenue (CNY Mn)

880.213.3

Overseas share of revenue (%)

31.04.4

Capital Markets

ItemValueDate / source

Total shares

~646.5 M

2026, Sohu/CFI.cn

Tradable A-shares

~630 M

Aug 2026, CFI.cn

Last verified close

RMB 6.15

mid-Aug 2026, CFI.cn

Buyback execution range

RMB 5.35–6.32

Jul–Sep 2026

GM purchase prices

RMB 4.53–4.99

Jan–Jul 2026

IPO price

RMB 18.39 (unadjusted)

Apr 2017

Book value per share

RMB 5.76

30 Jun 2026

Valuation Snapshot

MultipleValueBasis

Market cap

~RMB 3.98 bn

646.5 M × RMB 6.15

P/B

~1.07x

BVPS RMB 5.76 (Jun 2026)

P/S (TTM)

~6.1x

TTM revenue RMB 654.6 M (FY2025 − H1 2025 + H1 2026)

EV/Sales (TTM)

~4.5x

EV ≈ market cap − ~RMB 1.0 bn net cash (end-2025 basis)

EV/EBITDA

Not computed

—

Capital Markets — FY2024 dividend

ItemDetail

FY2024 dividend

None (no cash dividend, no bonus shares, no capitalisation)

2025 buyback

Treasury stock rose from RMB 65.1 M (end-2024) to RMB 110.1 M (Sep 2025), financed partly by special buyback loan

2026 buyback

Approved 23 Jul 2026; RMB 75–150 M; max price RMB 7.84; 3-month term to 22 Oct 2026; 21.5736 M shares (3.34%) for RMB 125 M by 30 Sep 2026; repurchased shares to be sold via centralised bidding 12 months after completion and within 3 years, otherwise cancelled

Analyst Conclusions

Management guidance

No numerical guidance. Management describes FY2025 as the first full year of HPV VBP with its effect "fully released", expects lab-segment cost control to improve in 2026, and targets higher overall profitability through new-product expansion, specialty lab testing, hospital upgrades and receivable collection (FY2025 AR).

Bull case

  1. Receivable optionality: gross pandemic receivables of RMB 1,075 M are carried at RMB 231 M; with national debt-swap funding, even partial recovery above book drives impairment reversals (already RMB 30.4 M in H1 2026) and cash inflows (FY2025 cash collected RMB 1,078 M).

  2. Base effects and mix: VBP is fully in the base; the 74.6% gross-margin reagent business, with non-VBP HPV triage, pharmacogenomics (~RMB 25 M, fast-growing) and new birth-defect assays, can return revenue to growth.

  3. Valuation floor: P/B ~1.1x with ~RMB 1 bn net cash (~25% of market cap), 3.34% buyback, and GM insider buying provide downside support.

Bear case

  1. No organic growth yet: revenue −17.9% in FY2025 and −4.7% in H1 2026; gross profit fell YoY in H1 2026.

  2. Low-quality profits: H1 2026 profit relied on impairment reversals, halved selling expense, FX and fair-value gains; core lab and hospital segments remain loss-making.

  3. Capital allocation: cash directed to non-core robotics, AI psychology, cultural media and donations while paying no dividend; repurchased shares are slated for resale rather than cancellation.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTiming
Buyback completion and total size22 Oct 2026
Q3 2026 report: revenue trajectory, impairment reversalsLate Oct 2026
Chloroquine phosphate gel Phase III initiation2026–27
Registrations: norovirus, vaginal microbiome; trial readouts for bladder/NPC methylation, SMA, HBV high-sensitivity2026–27
Amisen HK IPO outcome (fair-value gain)Pending
Further lab closures/consolidation; lab subsidiary breakevenOngoing
Kanghe hospital: linac installation, new departments, revenue scale2026–27
FY2026 annual report and dividend decisionApr 2027
Any new VBP rounds touching STD, thalassaemia or other assaysPolicy-dependent
Shareholder reductions by Yunnan Zhonghezhi/Guotiao fundOngoing

Analyst verdict

Hybribio is a company emerging from a classic pandemic hangover, and the H1 2026 return to profit should be read as the end of the write-down phase rather than the start of a growth phase. The core asset—a high-margin, evidence-rich HPV and women's-health reagent franchise with leading VBP volume—remains intact and continues to throw off cash, as FY2025 operating cash flow of RMB 341.6 M against a reported loss demonstrates. The balance sheet is the company's best defence: about RMB 1 bn of cash and deposits, negligible debt, and receivables that have already been written down by RMB 948 M, leaving recovery upside rather than further downside on the pandemic book.

What is missing is evidence of organic revenue growth. Molecular diagnostics revenue has not yet stabilised under VBP and the VAT change, the lab network still operates at single-to-low-teens gross margins, and the hospital will take years to scale. Earnings in 2026 are being supported by provision releases, cost cuts and FX—none of which is repeatable indefinitely. Capital allocation is also a legitimate concern: investments in robotics, AI psychology and cultural media, alongside donations, sit awkwardly beside a no-dividend policy, and repurchased shares are earmarked for resale rather than cancellation.

At roughly 1.1x book and about 4.5x EV/sales on our estimates, the market already prices the company as an ex-growth asset with cash backing. The risk/reward is therefore asymmetric to the upside only if three things happen within 12–18 months: HPV triage and pharmacogenomic products reignite reagent growth, the lab subsidiary approaches breakeven after closures, and receivable recoveries continue at FY2025's pace. Until revenue turns positive on a full-year basis, we would characterise Hybribio as a balance-sheet-supported special situation rather than a quality compounder, with the Q3 2026 report and FY2026 dividend decision as the next tests of management's credibility.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleNotesSource

Guan Qiaozhong (管乔中)

Chairman; legal representative; responsible person signing financial statements

Founder-chairman; chaired 2025 AGM (19 May 2026)

FY2024/2025 ARs; AGM resolution 2026-038

Wang Jianyu (王建瑜)

Director, General Manager; one of the actual controllers

Foreign (Hong Kong-resident) natural person; 1.69% direct stake end-2025 rising to 2.71% by 23 Jul 2026; mother of Guan Zhisheng

FY2025 AR; announcement 2026-049, 2026-054

Guan Zhisheng (管秩生)

One of the actual controllers; 0.56% direct holder

—

FY2025 AR

Li Qinghui (李庆辉)

Head of accounting (CFO-equivalent)

Signs financial statements

FY2024 AR; 2025 Interim

Luo Cuihong (罗翠红)

Head of accounting department

—

FY2024 AR

Chen Yi (陈毅)

Board Secretary

IR contact

FY2025 AR

Yuan Xian (袁娴)

Securities Affairs Representative

—

FY2025 AR

Prof. Li Xiaochuan (李晓川)

Chief Medical Officer; head of Kanghe oncology centre

Tenured professor of radiation oncology, Medical College of Wisconsin

FY2025 AR

Dr. Xie Longxu (谢龙旭)

Chief Scientist

Co-author of a 2020 Chinese Journal of Oncology award-winning HPV12+2 screening paper; disposed of shares in Jan 2026

FY2025 AR; Sohu insider-trading list

Shareholding Trend

ShareholderType31 Dec 2025 stake23 Jul 2026 stake

Hong Kong Technology Venture Co., Ltd. (香港科技创业股份有限公司)

Overseas corporate (controlling shareholder)

29.88% (193.20 M shares)

29.88%

Yunnan Zhonghezhi Enterprise Management Co., Ltd.

Domestic non-state

6.21% (25.93 M shares pledged)

5.00%

Shenzhen Guotiao-CMB M&A Equity Investment Fund (LP)

Domestic non-state (state-linked fund)

4.76%3.98%

Yunnan Yanchen Enterprise Management Co., Ltd.

Domestic non-state

2.26% (9.89 M pledged)

1.04%

Wang Jianyu

Overseas individual (controller)

1.69%2.71%

Beijing Xinweigang Technology Co., Ltd.

Domestic

not in top 10

1.56%

Long Xifu

Domestic individual

0.59%

not in top 10

Zhao Xuefang

Domestic individual

0.57%0.58%

Guan Zhisheng

Overseas individual (controller)

0.56%0.56%

Qi Yufeng

Domestic individual

0.49%

not in top 10

Yongying CSI All-Share Medical Devices ETF

Fund

0.30%0.44%

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs. Hybribio

HPV / women's-health MDx

Daan Gene (达安基因, 002030.SZ)

Broad PCR MDx player, competitor in HPV VBP

HPV / infectious MDx

Sansure Biotech (圣湘生物, 688289.SH)

Larger, diversifying via M&A (growth hormone, HLA); FY2025 revenue RMB 1,642 M, net profit RMB 199 M

HPV / genomics

BGI Genomics (华大基因)

Sequencing-based screening incl. HPV

HPV / multiplex

Tellgen (透景生命)

HPV and tumour marker panels

Global HPV

Roche Diagnostics (cobas HPV)

Premium hospital segment, automation

Global HPV

Hologic (Aptima HPV mRNA)

mRNA-based triage competitor

Global HPV/MDx

Qiagen; Becton Dickinson (Onclarity); Abbott

Global brands in tertiary hospitals

Thalassaemia/deafness genetics

Yaneng Bio (亚能生物); CapitalBio

Direct competitors in hereditary screening

ICL

KingMed Diagnostics (金域医学, 603882.SH)

Market leader in Chinese ICL

ICL

Dian Diagnostics (迪安诊断, 300244.SZ)

No.2 ICL; FY2025 revenue RMB 10,096 M (−17.2%), attributable profit RMB 44 M

ICL

Adicon (艾迪康)

National ICL chain

Peer Comparison FY2025

MetricHybribioSansure BiotechDian Diagnostics

Revenue

669.61,64210,096

Revenue growth (%)

-17.912.6-17.2

Attributable net profit

-130.919944

Net margin (%)

-19.612.10.4

R&D % of revenue

11.5——

Recent Developments

--

Company Snapshot

$93.1M

Revenue

10

Employees

2003

Founded

Guangdong, China

Headquarters

SWOT Analysis

Strengths

  • HPV leadership: first in national HPV-DNA VBP demand (3.37 M person-tests, 24.17%); >83 M cumulative tests (FY2025 AR).
  • High reagent gross margin: molecular diagnostics gross margin 74.64% in H1 2026 despite VBP (2026 Interim).
  • Balance-sheet strength: RMB 1,038.7 M cash/deposits at end-2025; debt ratio 11.93% (FY2025 AR; Q1 2026).
  • Cash generation: FY2025 OCF RMB 341.6 M (4.3x FY2024) while reporting a loss; cash collected RMB 1,078 M (FY2025 AR).
  • IP and registration depth: 225 patents, 97 registrations, 59 CE (26 IVDR) (FY2025 AR).
  • Controller alignment: GM bought RMB 12.04 M of stock in 2026; company repurchased 3.34% of shares (announcements 2026-049; 30 Sep 2026).

Weaknesses

  • Shrinking top line: revenue down four consecutive years to RMB 669.6 M (FY2025), −4.7% again in H1 2026.
  • Loss-making services: lab gross margin 13.58% and hospital −38.40% in H1 2026; lab subsidiary lost RMB 29.9 M in H1 2026.
  • Receivable quality: RMB 1,645 M gross receivables with RMB 948 M allowance; net receivables exceed annual revenue (FY2025 AR).
  • Earnings quality: H1 2026 profit relied on RMB 30.4 M impairment reversal and RMB 10.1 M fair-value gains (2026 Interim).
  • Pipeline slippage: raised-fund R&D and anti-HPV drug projects extended twice, now to Mar 2027 (2026 Interim).
  • Thin disclosure in English and on segment profits; no full-year segment operating income.

Opportunities

  • Screening policy: national targets of 70% cervical screening by 2030 (2023 action plan).
  • Non-VBP HPV triage: E6/E7 mRNA and methylation outside VBP (FY2025 AR).
  • Receivable recoveries: RMB 1,075 M gross pandemic receivables carried at only RMB 231 M; each recovery above book is pure profit (FY2025 AR).
  • Birth-defect portfolio: new STR kit (Mar 2026), SMA in trials; national 90% prenatal-screening target.
  • Pharmacogenomics: nine push products ~RMB 25 M and growing fast (FY2025 AR).
  • Investee monetisation: Amisen HK IPO filing; Salus and Jinshi sequencer stakes (FY2025 AR).

Threats

  • Further VBP rounds extending to other mature assays (FY2025 AR risk section).
  • ICL price war: sector peers Dian (−17.2% revenue FY2025) show structural pressure.
  • Local-government fiscal stress delaying collections despite debt-swap programmes.
  • Larger, acquisitive competitors (Sansure's multiple 2025–26 acquisitions).
  • Global platforms (Roche, Hologic, BD) in tertiary hospitals.
  • Policy/tax shocks: the 2025 VAT increase demonstrated sensitivity to fiscal rules.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
29 Apr 2025FY2024 AR: first annual loss since IPO (−RMB 654.9 M attributable); no dividendReset of earnings base
29 Apr 2025Q1 2025: revenue RMB 134.1 M (−26.78%), net loss RMB 27.3 M; OCF +RMB 46.9 M Q1 2025 reportVBP + VAT impact visible
26 Aug 2025H1 2025: revenue RMB 315.0 M (−22.96%); attributable loss RMB 89.6 M; lab revenue RMB 91.6 M (−18.85%); credit impairment RMB 57.6 M 2025 Interim; Securities StarLosses persist
19 Sep 2025Investor meeting: 31 labs operating; management signals H2 improvement as VBP effects fully absorbed IR recordGuidance tone
13 Oct 2025Sixth board, 2nd meeting: swaps RMB 9.39 M of self-funded project personnel costs with raised funds 2026 InterimHousekeeping
29 Oct 2025Q3 2025: Medical Science Park transferred to fixed assets; long-term borrowing up 81% to RMB 95.6 M (buyback loan); treasury stock RMB 110.1 M Q3 2025 reportCapex phase completing; buyback active
FY2025 (undated)RMB 20 M investment in Chengdu Jinshi; RMB 5.7 M follow-on in Gexili FY2025 ARUpstream sequencing/AI bets
FY2025 (undated)Respiratory 6-plex registered; internet hospital licence; Wuxian AI brain launched FY2025 ARPortfolio/digital
FY2025 (undated)Lab closures/mergers (Fuzhou, Jinan, Shijiazhuang, Chongqing, Hefei, Hangzhou, Yinchuan, Inner Mongolia) FY2025 ARCost restructuring
FY2025 (undated)Investee Amisen files for HK IPO FY2025 ARPotential fair-value gain
Jan 2026FY2025 loss guidance: −RMB 120 M to −195 M 36KrNarrowing loss
7 Jan 2026Chief Scientist Xie Longxu sells ~93,900 shares SohuMinor insider sale
9–13 Jan 2026GM Wang Jianyu buys ~5.9 M shares; announces ≥RMB 12 M purchase plan Sohu; announcement 2026-049Insider confidence
Feb 2026USD 6 M into Flexiv; RMB 18 M into Jingxiang; RMB 5.57 M acquisition of Chaozhou Hehehe FY2025 ARDiversification into AI/robotics/culture (governance question)
4 Mar 2026Chromosome STR kit registration FY2025 ARBirth-defect portfolio
Mar 2026RMB 35 M into Shenzhen Salus FY2025 ARDomestic sequencer ecosystem
18 Mar 2026Sixth board, 4th meeting: R&D and anti-HPV projects extended to Mar 2027 2026 InterimPipeline delays
29 Apr 2026FY2025 AR and Q1 2026: FY2025 revenue RMB 669.6 M (−17.89%), loss RMB 130.9 M (−80% narrower); receivables down RMB 378 MStabilisation
14 May 2026Online results briefing 2026 InterimIR
May 2026Yunnan Zhonghezhi reduction touches 5% threshold SZSE.ioOverhang
May 2026Wholly-owned subsidiary obtains medical device registration certificate SZSE.ioPortfolio
19 May 20262025 AGM approves all resolutions including no dividend, remuneration system, auditor reappointment Announcement 2026-038Governance
Jun 2026Planned charitable donations of up to RMB 30 M disclosed; investors question this vs. no dividend SZSE IR Q&ACapital-allocation controversy
1 Jul 2026Wang Jianyu purchase plan adds centralised-bidding method Announcement 2026-046—
Jul 2026Wang Jianyu plan completed: 2.564 M shares, RMB 12.04 M Announcement 2026-049Insider buying done
2 Jul 2026Invention patent grants to company and subsidiaries CFI.cnIP
23 Jul 2026Board approves RMB 75–150 M buyback, max RMB 7.84/share, 3-month window, funded by own cash and special bank loan Caiwen NewsShareholder return
14 Aug 2026H1 2026: revenue RMB 300.0 M (−4.74%), attributable profit RMB 31.26 M (turnaround) Caiwen News; 2026 InterimInflection
21 Aug 2026Buyback exceeds 3% of share capital CFI.cnExecution
15 Sep 2026Results briefing: 21.57 M shares repurchased for ~RMB 125 M; chloroquine gel Phase II complete 10jqka/Securities StarExecution
30 Sep 2026Buyback progress: 21.5736 M shares (3.34%), RMB 5.35–6.32/share, RMB 125 M Caiwen NewsNear upper half of range
22 Oct 2026 (upcoming)Buyback window expires Caiwen NewsMonitorable

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 315 Mn in H1 2025 to CNY 300 Mn in H1 2026.
Guangdong Hybribio Biotech Co., Ltd. — Income Statement: Revenue & Gross Profit
Series (CNY Mn)H1 2025H1 2026
Revenue315300
Cost of revenue167158

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Guangdong Hybribio Biotech, FY2025 Annual Report summary, China Securities Journal disclosure page B168, 29 Apr 2026 (epaper.cs.com.cn)
  2. Hybribio FY2025 MD&A (reproduced), Securities Star, 7 May 2026 (stock.stockstar.com)
  3. Hybribio FY2024 Annual Report extract (announcement 2025-022), Pharnexcloud (pharnexcloud.com)
  4. Hybribio FY2025 Annual Report header figures, Pharnexcloud (pharnexcloud.com)
  5. Hybribio FY2023 Annual Report summary, China Securities Journal, 24 Apr 2024 (epaper.cs.com.cn)
  6. Hybribio 2025 Interim Report summary, China Securities Journal, 26 Aug 2025 (epaper.cs.com.cn)
  7. Hybribio Q3 2025 Report (2025-064), CNINFO (static.cninfo.com.cn)
  8. Hybribio Q1 2025 Report extract, Pharnexcloud (pharnexcloud.com)
  9. Hybribio 2026 Interim MD&A and segment data, CFI.cn: and: quote.cfi.cn · quote.cfi.cn
  10. CFI.cn quote and financial pages · quote.cfi.cn
  11. H1 2026 results flash, Caiwen News, 14 Aug 2026 (caiwennews.com)
  12. Buyback progress, Caiwen News, 30 Sep 2026 (caiwennews.com)
  13. Buyback top-10 holders announcement (2026-054), CNINFO (static.cninfo.com.cn)
  14. GM share purchase completion (2026-049) (pdf.dfcfw.com)
  15. 2025 AGM resolution (2026-038), CNINFO (static.cninfo.com.cn)
  16. Results briefing, 15 Sep 2026, 10jqka/Securities Star (stock.10jqka.com.cn)
  17. Investor-relations record, Sept 2025 (FXBaogao) (fxbaogao.com)
  18. Q3 2024 analyst meeting record, Securities Star (wap.stockstar.com)
  19. SZSE investor interactions (Lixinger) (lixinger.com)
  20. Sohu company profile / insider trades (q.stock.sohu.com)
  21. SZSE.io announcement tracker (szse.io)
  22. FY2025 loss guidance, 36Kr (pitchhub.36kr.com)
  23. H1 2025 results summary, Securities Star (stock.stockstar.com)
  24. 2021 H1 coverage, Economic Observer via 36Kr (36kr.com)
  25. FY2022 results, NBD · Q3 2022, NBD
  26. H1 2022 revenue mix, China Baogao (chinabaogao.com)
  27. Jiemian on H1 2022 lab revenue (m.jiemian.com)
  28. China Securities Journal, Nov 2020 company profile (cs.com.cn)
  29. Sansure FY2025 results, CLS/STAR Market Daily · CSC Securities note
  30. Dian Diagnostics FY2025 results, Jiemian · Orient Securities via Gelonghui

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.